Following 5 years of success, the 6th Annual World Orphan Drug Congress USA 2015 is once again gearing up to bring together stakeholders from all over the world. From humble beginnings as a small conference that brought together the few pioneers spearheading the progress in orphan drugs development it became known as the event that brought this community together. It is testament to how the industry has grown that now there are 3 simultaneous conference streams and an exhibition hall of over 40 stands at the Washington Hilton in D.C.
In 2015, World Orphan Drug Congress USA was packed with great content on sustainability, pricing and reimbursement, commercialization and market access. To grow the breadth of the event even further and empower patient groups like never before, we launched Rare Disease Advocacy World. Pitch and Partner also grew from 20 to 40 presenters, making this a favorite of investors.
This is the largest global industry gathering for the orphan drug industry and rare disease community where pharma, biotech, patient groups, academia, regulators, payers and investors gather to talk about strategies to expedite orphan drug development. We grew the event to 600 participants in 2015 with over 25 countries represented.
Academic medical centers, HCPs, clinicians and point of care diagnostics will be a new focus in 2016. Specific orphan products and their Marketing Managers will also be a stronger focus along with gene therapy as the future rare disease cure.
Meet CEOs, VPs and Directors of the following business units from pharma and biotech: RandD, Business Development, Regulatory Access, Market Access, Commercial, Marketing and Brand/Product Managers.You will also meet Scientists, Investigators and Engineers as well as relevant Heads from university departments studying rare disease and developing a cure.
In 2015, World Orphan Drug Congress USA was packed with great content on sustainability, pricing and reimbursement, commercialization and market access. To grow the breadth of the event even further and empower patient groups like never before, we launched Rare Disease Advocacy World. Pitch and Partner also grew from 20 to 40 presenters, making this a favorite of investors.
This is the largest global industry gathering for the orphan drug industry and rare disease community where pharma, biotech, patient groups, academia, regulators, payers and investors gather to talk about strategies to expedite orphan drug development. We grew the event to 600 participants in 2015 with over 25 countries represented.
Academic medical centers, HCPs, clinicians and point of care diagnostics will be a new focus in 2016. Specific orphan products and their Marketing Managers will also be a stronger focus along with gene therapy as the future rare disease cure.
Meet CEOs, VPs and Directors of the following business units from pharma and biotech: RandD, Business Development, Regulatory Access, Market Access, Commercial, Marketing and Brand/Product Managers.You will also meet Scientists, Investigators and Engineers as well as relevant Heads from university departments studying rare disease and developing a cure.
